{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:03:13Z","timestamp":1790755393387,"version":"4.1.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The use of monoclonal antibodies (mAbs) has revolutionized the treatment of autoimmune, inflammatory, and neoplastic diseases. However, accumulating evidence indicates that biologic therapies may be associated with renal adverse events, including various types of glomerulonephritis. The aim of this review was to summarize all reports available in the scientific literature regarding the occurrence of IgA nephropathy after monoclonal antibody treatment. Additionally, the risk of other glomerulonephritis after biologic therapy was discussed. IgA nephropathy (IgAN) is the most commonly reported glomerular lesion associated with monoclonal antibody therapy, particularly with TNF-\u03b1 inhibitors such as infliximab, adalimumab, golimumab, and etanercept, as well as with immune checkpoint inhibitors targeting the PD-1 (pembrolizumab, nivolumab) and interleukin (ustekinumab) pathways. Proposed mechanisms include immune dysregulation with a shift toward Th2 and Th17-dependent responses, increased production of galactose-deficient IgA1, complement activation, formation of circulating immune complexes, and loss of immune tolerance. In some cases, drug discontinuation and glucocorticoid therapy have resulted in partial or complete disease remission, although progression to end-stage renal disease has also been reported. Due to the potential severity of these complications, initial and periodic monitoring of renal function and urinalysis are recommended in patients receiving monoclonal antibody therapy. Early recognition of renal involvement and prompt treatment modification can improve prognosis.<\/jats:p>","DOI":"10.3389\/fphar.2026.1891000","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:47:11Z","timestamp":1790754431000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Monoclonal antibodies associated IgA nephropathy or other nephropathies"],"prefix":"10.3389","volume":"17","author":[{"given":"Mi\u0142osz","family":"Miedziaszczyk","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences","place":["Poznan, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gracjan","family":"Kosiorowski","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences","place":["Poznan, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Kubasik","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences","place":["Poznan, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Grabowski","sequence":"additional","affiliation":[{"name":"Department of Inorganic Chemistry, Medical University of Gdansk","place":["Gdansk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Sza\u0142ek","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences","place":["Poznan, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk Chun","family":"Szeto","sequence":"additional","affiliation":[{"name":"Carol & Richard Yu Peritoneal Dialysis Research Centre, Prince of Wales Hospital, Department of Medicine & Therapeutics, The Chinese University of Hong Kong","place":["Hong Kong, Hong Kong SAR, China"]},{"name":"Li Ka Shing Institute of Health Sciences (LiHS), Faculty of Medicine, The Chinese University of Hong Kong","place":["Hong Kong, Hong Kong SAR, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Idasiak-Piechocka","sequence":"additional","affiliation":[{"name":"Department of General and Transplant Surgery, Poznan University of Medical Sciences","place":["Poznan, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1097\/MJT.0000000000000946","article-title":"Golimumab-associated glomerulonephritis","volume":"28","author":"Agrawal","year":"2021","journal-title":"Am. J. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/08998280.2021.1885285","article-title":"Worsening of renal function and uncontrolled hypertension from intravitreal bevacizumab injections","volume":"34","author":"Ahmed","year":"2021","journal-title":"Proc. Bayl Univ. Med. Cent."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00467-009-1322-7","article-title":"Membranoproliferative glomerulonephritis","volume":"25","author":"Alchi","year":"2010","journal-title":"Pediatr. Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1874312901206010315","article-title":"Anti-tumor necrosis factor-alpha induced systemic lupus erythematosus","volume":"6","author":"Almoallim","year":"2012","journal-title":"Open Rheumatol. J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e19110","DOI":"10.7759\/cureus.19110","article-title":"Nivolumab-induced crescentic immunoglobulin A nephropathy with Henoch-Schonlein purpura features in a patient diagnosed with hepatocellular carcinoma","volume":"13","author":"Asemota","year":"2021","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ekir.2018.10.017","article-title":"Immune check point inhibitor-associated glomerulonephritis","volume":"4","author":"Ashour","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1196\/annals.1361.100","article-title":"Autoimmunity and anti-TNF-alpha agents","volume":"1051","author":"Atzeni","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.1200\/JCO.2009.23.5622","article-title":"American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer","volume":"27","author":"Azzoli","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e237713","DOI":"10.1136\/bcr-2020-237713","article-title":"Onset of IgA nephropathy in a patient treated with infliximab for ankylosing spondylitis","volume":"14","author":"Baert","year":"2021","journal-title":"BMJ Case Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1053\/j.ajkd.2017.08.008","article-title":"Interstitial nephritis secondary to vedolizumab treatment in crohn disease and safe rechallenge using steroids: a case report","volume":"71","author":"Bailly","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ejca.2020.08.005","article-title":"A case of schonlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma","volume":"139","author":"Belkaid","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-226442","article-title":"Adalimumab-induced IgA nephropathy","volume":"12","author":"Bhagat Singh","year":"2019","journal-title":"BMJ Case Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1590\/1806-9282.64.07.568","article-title":"Metastatic colorectal cancer: treatment with panitumumab","volume":"64","author":"Brazilian Medical","year":"2018","journal-title":"Rev. Assoc. Med. Bras."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.3899\/jrheum.160147","article-title":"Development of nephrotic syndrome in a patient with rheumatoid arthritis treated with certolizumab","volume":"43","author":"Butendieck","year":"2016","journal-title":"J. Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/ICU.0000000000000424","article-title":"Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T","volume":"28","author":"Cai","year":"2017","journal-title":"Curr. Opin. Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","article-title":"Mechanism of action of rituximab","volume":"13","author":"Cerny","year":"2002","journal-title":"Anticancer Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1393901","DOI":"10.3389\/fimmu.2024.1393901","article-title":"Immune checkpoint inhibitor therapy associated with IgA nephropathy: a case report and literature review","volume":"15","author":"Chabannes","year":"2024","journal-title":"Front. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1093\/ndt\/gfi180","article-title":"Infliximab and nephrotic syndrome","volume":"20","author":"Chin","year":"2005","journal-title":"Nephrol. Dial. Transpl."},{"key":"B23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40265-014-0239-z","article-title":"Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis","volume":"74","author":"Dhillon","year":"2014","journal-title":"Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","article-title":"Off-label uses of omalizumab","volume":"50","author":"El-Qutob","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/nm939","article-title":"Lasker clinical medical research award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases","volume":"9","author":"Feldmann","year":"2003","journal-title":"Nat. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.bbmt.2018.11.013","article-title":"Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: a retrospective record review","volume":"25","author":"Floisand","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/24725625.2020.1798061","article-title":"Rapidly progressive glomerulonephritis after introduction of certolizumab pegol: a case report","volume":"5","author":"Funada","year":"2021","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"B96","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","article-title":"Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors","volume":"74","author":"Gallan","year":"2019","journal-title":"Am. J. Kidney. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/03007995.2021.2015155","article-title":"IgA nephropathy in a child: crohn's disease-associated or adalimumab induced?","volume":"38","author":"Graziano","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"B30","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3390\/biom11040513","article-title":"Mechanisms of primary membranous nephropathy","volume":"11","author":"Gu","year":"2021","journal-title":"Biomolecules"},{"key":"B31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ckj\/sfv139","article-title":"Minimal change disease onset observed after bevacizumab administration","volume":"9","author":"Hanna","year":"2016","journal-title":"Clin. Kidney J."},{"key":"B32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4081\/reumatismo.2003.76","article-title":"Kidney involvement in rheumatoid arthritis","volume":"55","author":"Icardi","year":"2003","journal-title":"Reumatismo"},{"key":"B33","article-title":"Diffuse proliferative Glomerulonephritis(Archived)","author":"Ikhlas","year":"2026","journal-title":"StatPearls. (Treasure Isl. (FL))"},{"key":"B34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1053\/j.ajkd.2016.09.011","article-title":"Panitumumab-induced immune complex glomerulonephritis","volume":"69","author":"Izzedine","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1093\/ndt\/gfp314","article-title":"IgA nephropathy associated with ankylosing spondylitis is not controlled by Infliximab therapy","volume":"24","author":"Jacquet","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"key":"B36","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s13730-020-00457-x","article-title":"Crescentic IgA nephropathy after administration of human monoclonal interleukin-12\/23p40 antibody in a patient with crohn's disease: a case report","volume":"9","author":"Kanazawa","year":"2020","journal-title":"Cen. Case Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.monrhu.2014.06.001","article-title":"Atteintes r\u00e9nales dans les spondyloarthrites","volume":"82","author":"Karras","year":"2015","journal-title":"Rev. Du. Rhum. Monogr."},{"key":"B38","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/ckj\/sfz074","article-title":"Relapse of membranous nephropathy with cancer immunotherapy","volume":"14","author":"Kim","year":"2021","journal-title":"Clin. Kidney J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13730-019-00414-3","article-title":"A case of denosumab-associated membranous nephropathy in a patient with rheumatoid arthritis","volume":"9","author":"Kimoto","year":"2020","journal-title":"Cen. Case Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","article-title":"IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma","volume":"57","author":"Kishi","year":"2018","journal-title":"Intern Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/ijd.12622","article-title":"Psoriasis-associated IgA nephropathy under infliximab therapy","volume":"54","author":"Kluger","year":"2015","journal-title":"Int. J. Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5414\/CN108901","article-title":"Thrombotic microangiopathy associated with cetuximab, an epidermal growth factor receptor inhibitor","volume":"87","author":"Koizumi","year":"2017","journal-title":"Clin. Nephrol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40259-020-00416-z","article-title":"Certolizumab pegol: a review in moderate to severe plaque psoriasis","volume":"34","author":"Lee","year":"2020","journal-title":"BioDrugs"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e15330","DOI":"10.1111\/1756-185X.15330","article-title":"Case report: crescentic IgA nephropathy with anti-neutrophil cytoplasmic antibodies, in a patient on golimumab","volume":"27","author":"Lee","year":"2024","journal-title":"Int. J. Rheum. Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/ajg.2009.500","article-title":"A case report of nephrotic syndrome due to intake of certolizumab pegol in a patient with crohn's disease","volume":"105","author":"Leong","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"20406223221106878","DOI":"10.1177\/20406223221106878","article-title":"Elevated activating Fc gamma receptors levels correlated with susceptibility and severity of IgA nephropathy","volume":"13","author":"Li","year":"2022","journal-title":"Ther. Adv. Chronic Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1053\/j.ajkd.2018.09.013","article-title":"Acute thrombotic microangiopathy and cortical necrosis following administration of alemtuzumab: a case report","volume":"73","author":"Liou","year":"2019","journal-title":"Am. J. Kidney Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/14740338.2017.1323864","article-title":"The safety of ustekinumab for the treatment of psoriatic arthritis","volume":"16","author":"Lopez-Ferrer","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1681\/ASN.2011080822","article-title":"Fcgamma receptor deficiency attenuates diabetic nephropathy","volume":"23","author":"Lopez-Parra","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"7964015","DOI":"10.1155\/2017\/7964015","article-title":"Cetuximab-associated crescentic diffuse proliferative glomerulonephritis","volume":"2017","author":"Manthri","year":"2017","journal-title":"Case Rep. Nephrol."},{"key":"B52","first-page":"840","article-title":"Membranous nephropathy in rheumatoid arthritis: a case report","volume":"27","author":"Maruotti","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000515585","article-title":"IgA nephropathy in a patient treated with adalimumab","volume":"11","author":"Mertelj","year":"2021","journal-title":"Case Rep. Nephrol. Dial."},{"key":"B54","doi-asserted-by":"publisher","first-page":"583","DOI":"10.17219\/acem\/171000","article-title":"Assessment of serum concentration and urinary excretion of tumor necrosis factor receptor 1 and 2 and their potential as markers of immunoglobulin A nephropathy activity","volume":"33","author":"Miedziaszczyk","year":"2024","journal-title":"Adv. Clin. Exp. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.21873\/invivo.13975","article-title":"IgA nephropathy associated with Infliximab treatment in patients with crohn's disease: study of IgA1 and IgA2 expression in glomeruli","volume":"39","author":"Mima","year":"2025","journal-title":"Vivo"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.2169\/internalmedicine.7115-21","article-title":"IgA nephropathy that developed as an immune-related adverse event of pembrolizumab complicated with interstitial nephritis","volume":"61","author":"Mitarai","year":"2022","journal-title":"Intern Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.nefroe.2023.02.010","article-title":"IgA nephropathy after long-term treatment with infliximab for crohn's disease crohn's disease, a review of two cases","volume":"44","author":"Montero","year":"2024","journal-title":"Nefrol. Engl. Ed."},{"key":"B58","article-title":"Development of mesangial immunoglobulin IgA glomerulonephritis and p-ANCA positivity in a patient with psoriatic arthritis","volume":"33","author":"Nazzaro","year":"2016","journal-title":"G. Ital. Nefrol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B60","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s13730-024-00885-z","article-title":"A case diagnosed with IgA nephropathy during a complete remission of minimal change nephrotic syndrome treated with rituximab","volume":"13","author":"Nishikawa","year":"2024","journal-title":"Cen. Case Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2169\/internalmedicine.3928-19","article-title":"Renal effects after pembrolizumab treatment for non-small cell lung carcinoma","volume":"59","author":"Oki","year":"2020","journal-title":"Intern Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.nefro.2018.06.003","article-title":"Nephrotic syndrome in relation to treatment with ustekinumab","volume":"39","author":"Perez Fernandez","year":"2019","journal-title":"Nefrol. Engl. Ed."},{"key":"B63","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3265\/Nefrologia.pre2014.Mar.12388","article-title":"Relapse of minimal change disease nephrotic syndrome after administering intravitreal bevacizumab","volume":"34","author":"Perez-Valdivia","year":"2014","journal-title":"Nefrologia"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1177\/1352458519841829","article-title":"Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis","volume":"25","author":"Phelps","year":"2019","journal-title":"Mult. Scler."},{"key":"B65","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.pharma.2018.07.005","article-title":"Berger's disease associated to an adalimumab-treated rheumatoid arthritis","volume":"76","author":"Pierrot","year":"2018","journal-title":"Ann. Pharm. Fr."},{"key":"B66","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/ki.2010.89","article-title":"Acute interstitial nephritis","volume":"77","author":"Praga","year":"2010","journal-title":"Kidney Int."},{"key":"B67","doi-asserted-by":"publisher","first-page":"9480860","DOI":"10.1155\/2020\/9480860","article-title":"The association of TNF-alpha inhibitors and development of IgA nephropathy in patients with rheumatoid arthritis and diabetes","volume":"2020","author":"Premuzic","year":"2020","journal-title":"Case Rep. Nephrol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.kint.2021.02.030","article-title":"The case | membranous nephropathy after alemtuzumab treatment","volume":"100","author":"Rabant","year":"2021","journal-title":"Kidney Int."},{"key":"B70","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1089\/jayao.2020.0077","article-title":"Ewing's sarcoma in a patient with crohn's disease treated with ustekinumab: a case report","volume":"10","author":"Rao","year":"2021","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B72","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal segmental glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1517\/14712591003724670","article-title":"The use of ustekinumab in autoimmune disease","volume":"10","author":"Ryan","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1053\/j.ajkd.2013.01.008","article-title":"Diffuse proliferative glomerulonephritis associated with cetuximab, an epidermal growth factor receptor inhibitor","volume":"61","author":"Sasaki","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1111\/ped.12017","article-title":"Relapse of minimal change nephrotic syndrome after intravitreal bevacizumab","volume":"55","author":"Sato","year":"2013","journal-title":"Pediatr. Int."},{"key":"B76","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12882-020-02015-0","article-title":"IgA nephropathy in a patient receiving infliximab for generalized pustular psoriasis","volume":"21","author":"Segawa","year":"2020","journal-title":"BMC Nephrol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s13730-023-00836-0","article-title":"Active flare of IgA nephropathy during long-term therapy with anti-tumor necrosis factor-alpha antibody drugs for crohn's disease: three case reports and literature review","volume":"13","author":"Shimizu","year":"2024","journal-title":"Cen. Case Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/ckj\/sfaa049","article-title":"Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy","volume":"13","author":"Shye","year":"2020","journal-title":"Clin. Kidney J."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e243568","DOI":"10.1136\/bcr-2021-243568","article-title":"Acute interstitial nephritis secondary to vedolizumab","volume":"14","author":"Simpson","year":"2021","journal-title":"BMJ Case Rep."},{"key":"B80","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41581-022-00630-8","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury","volume":"18","author":"Sprangers","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","article-title":"Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis","volume":"20","author":"Stokes","year":"2005","journal-title":"Nephrol. Dial. Transpl."},{"key":"B82","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1517\/14740338.2014.915024","article-title":"Panitumumab safety for treating colorectal cancer","volume":"13","author":"Stremitzer","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e00462","DOI":"10.14309\/crj.0000000000000462","article-title":"IgA nephropathy in the setting of Anti-TNF-alpha therapy for inflammatory bowel disease","volume":"7","author":"Strobel","year":"2020","journal-title":"ACG Case Rep. J."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e00788","DOI":"10.14309\/crj.0000000000000788","article-title":"Vedolizumab-induced acute interstitial nephritis in ulcerative colitis","volume":"9","author":"Subhaharan","year":"2022","journal-title":"ACG Case Rep. J."},{"key":"B85","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40265-020-01437-2","article-title":"Alemtuzumab: a review in relapsing remitting multiple sclerosis","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1046\/j.1523-1755.2002.00193.x","article-title":"Polymorphism of the cytokine genes and IgA nephropathy","volume":"61","author":"Syrjanen","year":"2002","journal-title":"Kidney Int."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e20464","DOI":"10.1097\/MD.0000000000020464","article-title":"Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer: a case report","volume":"99","author":"Tanabe","year":"2020","journal-title":"Med. Baltim."},{"key":"B88","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"B89","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s13730-025-01078-y","article-title":"IgA nephropathy with rheumatoid arthritis related to adalimumab","volume":"15","author":"Tufekci","year":"2026","journal-title":"Cen. Case Rep."},{"key":"B90","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/ndt\/gfg010","article-title":"Polymorphisms of the tumour necrosis factor alpha gene at position -308 and TNFd microsatellite in primary IgA nephropathy","volume":"18","author":"Tuglular","year":"2003","journal-title":"Nephrol. Dial. Transpl."},{"key":"B91","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with Anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-237008","article-title":"IgA nephropathy after pembrolizumab therapy for mesothelioma","volume":"13","author":"Wang","year":"2020","journal-title":"BMJ Case Rep."},{"key":"B93","doi-asserted-by":"publisher","first-page":"812781","DOI":"10.1155\/2013\/812781","article-title":"Adalimumab (TNF alpha inhibitor) therapy exacerbates IgA glomerulonephritis acute renal injury and induces lupus autoantibodies in a psoriasis patient","volume":"2013","author":"Wei","year":"2013","journal-title":"Case Rep. Nephrol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.clinthera.2005.06.003","article-title":"Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer","volume":"27","author":"Wong","year":"2005","journal-title":"Clin. Ther."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2324709620946890","DOI":"10.1177\/2324709620946890","article-title":"Acute interstitial nephritis: a rare and unusual side effect of omalizumab","volume":"8","author":"Yang","year":"2020","journal-title":"J. Investig. Med. High. Impact Case Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1891000\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:47:13Z","timestamp":1790754433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1891000\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":96,"alternative-id":["10.3389\/fphar.2026.1891000"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1891000","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1891000"}}